Skip to main content

Table 4 Univariate and multivariate analysis of overall survival (validation cohort, n = 247)

From: AGLR is a novel index for the prognosis of hepatocellular carcinoma patients: a retrospective study

Clinical character Univariate analysis Multivariate analysis
HR (95% CI) p value HR (95% CI) p value
AGLR level (> 90 vs ≤ 90) 2.47 (1.59–3.64)  < 0.001 1.82 (1.35–2.57)  < 0.001
Age, years (> 60 vs ≤ 60) 1.16 (0.77–1.76) 0.460   
Gender (male vs female) 1.49 (1.11–2.30) 0.096   
Drinking (yes vs no) 1.23 (0.88–1.71) 0.207   
HBsAg (positive vs negative) 1.10 (0.72–1.67) 0.639   
AFP, ng/ml (> 20 vs ≤ 20) 1.65 (1.13–2.65) 0.011 1.07 (0.81–1.44) 0.366
Liver cirrhosis (yes vs no) 1.03 (0.59–1.79) 0.801   
Tumor size, cm (> 5 vs ≤ 5) 2.11 (1.49–2.91)  < 0.001 1.69 (1.15–2.480) 0.008
Tumor number (multiple vs single) 1.63 (1.22–2.54) 0.013 1.20 (0.81–1.79) 0.307
TNM stage (III–IV vs I–II) 2.33 (1.83–3.50)  < 0.001 1.39 (1.07–2.10) 0.016
MVI (yes vs no) 2.81 (1.99–3.73)  < 0.001 2.30 (1.57–2.93)  < 0.001
Recurrence (yes vs no) 2.51 (1.64–3.51)  < 0.001 2.05 (1.46–2.79)  < 0.001
  1. CI, confidence interval; HR, hazard ratio; AGLR, alkaline phosphatase plus gamma-glutamyl transpeptidase to lymphocyte ratio; HBsAg, hepatitis B surface antigen; AFP, alpha-fetoprotein; TNM, tumor-node-metastasis; MVI, microvascular invasion